An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 9-10, 1997, Pages 720-726

  Maeda, Atsuyoshi ^a   Honda, Masaaki ^a   Kuramochi, Takehiko ^a   Tanaka, Koichi ^a   Takabatake, Toshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium transients; Delapril HCl; Doxorubicin; Neonatal rat heart

Indexed keywords

DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DRUG METABOLITE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOTOXICITY; CELL CULTURE; CONTROLLED STUDY; HEART PROTECTION; IN VITRO STUDY; MUSCLE CELL; NONHUMAN; RAT;

EID: 0030979690     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb02119.x     Document Type: Article

References (43)

1. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979; 32: 302-14.
2. 2+ release channel from rat cardiac sarcoplasmic reticulum: Possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol. Pharmacol. 1990; 37: 503-14.
3. Kim D-H, Landry AB III, Lee YS, Katz AM. Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J. Mol. Cell. Cardiol. 1989; 21: 433-6.
4. Boucek RJ Jr, Buck SH, Scott F, Oquist NL, Fleiscer S, Olson RD. Anthracycline-induced tension in permeabilized cardiac fibers: Evidence for the activation of the calcium release channel of sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 1993; 25: 249-59.
5. Holmberg SRM, Williams AJ. Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ. Res. 1990; 67: 272-83.
6. Ondrias K, Borgatta L, Kim DH, Ehrlich BE. Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ. Res. 1990; 67: 1167-74.
7. Dodd DA, Atkinson JB, Olson RD et al. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest. 1993; 91: 1697-705.
8. Wang Y-X, Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ. Res. 1995; 76: 645-53.
9. 2+ exchange of dog heart sarcolemmal vesicles. FEBS Lett. 1981; 130: 184-6.
10. Olson RD, Mushlin PS, Brenner DE et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl Acad. Sci. USA 1988; 85: 3585-9.
11. Gwathmey JK, Morgan JP. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ. Res. 1985; 57: 836-43.
12. Kuramochi T, Honda M, Tanaka K et al. Contrasting effects of angiotensin converting enzyme inhibitor and a calcium antagonist on calcium transients in isolated rat cardiac myocytes. Cardiovasc. Res. 1994; 28: 1407-13.
13. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J. 1990; 4: 3076-86.
14. Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: Early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat. Rep. 1978; 62: 887-9.
15. Speyer JL, Green MD, Kramer E et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med. 1988; 319: 745-52.
16. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429-35.
17. The SOLVED Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327: 685-91.
18. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 1992; 327: 669-77.
19. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996; 347: 297-9.
20. Honda M, Morioka S, Ohoka M, Yamada S, Moriyama K. Soluble factor from the hypertrophied left ventricle of dogs in experimental hypertension: Ability to stimulate protein metabolism of cultured heart cells. J. Hypertens. 1988; 6 (Suppl. 4): S125-7.
21. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM. Effect of verapamil on doxorubicin cardiotoxicity: Altered muscle gene expression in cultured neonatal rat cardiac myocytes. Cancer Res. 1993; 53: 4658-64.
22. Kuzuo H, Honda M, Tanaka K et al. Direct effects of angiotensin I. angiotensin II, an ACE inhibitor and a serine proteinase inhibitor on cultured heart cells from spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1995; 22: 82-6.
23. Steinberg SF, Robinson RB, Lieberman HB, Stern DM, Rosen MR. Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart. Circ. Res. 1991; 68: 1216-29.
24. Kuramochi T, Honda M, Tanaka K, Enomoto K, Hashimoto M, Morioka S. Calcium transients in single myocytes and membranous ultrastructures during the development of cardiac hypertrophy and heart failure in rats. Clin. Exp. Pharmacol. Physiol. 1994; 21: 1009-18.
25. Honda M, Kuramochi T, Ishinaga Y et al. Contrasting effects of isoproterenol and phosphodiesterase III inhibitor on intracellular calcium transients in cardiac myocytes from failing hearts. Clin. Exp. Pharmacol. Physiol. 1994; 21: 1001-8.
26. Calderone A, de Champlain J, Rouleau JL. Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J. Mol. Cell. Cardiol. 1991; 23: 333-42.
27. Jensen RA. Doxorubicin cardiotoxicity: Contractile change after long-term treatment in the rat. J. Pharmacol. Exp. Ther. 1986; 236: 197-203.
28. Seino Y, Tomita Y, Nagae Y et al. Cardioprotective effects of ACE-inhibitor (cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats. Circulation 1993; 88 (Suppl. I): 633 (Abstract).
29. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9.
30. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc. Natl Acad. Sci. USA 1982; 79: 3310-14.
31. Sharma JN, Fernandez PG, Kim B-K, Idikio H, Triggle CR. Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide. J. Hypertens. 1983; 1: 251-6.
32. Rump AFE, Rösen R, Korth A, Klaus W. Deleterious effect of exogenous angiotensin-I on the extent of regional ischaemia and its inhibition by captopril. Eur. Heart. J. 1993; 14: 106-12.
33. Rump AFE, Koreuber D, Rosen R, Klaus W. Cardioprotection by ramprilat in isolated rabbit hearts. Eur. J. Pharmacol. 1993; 241: 201-7.
34. Olson RD, Boerth RC, Gerber JG, Nies AS. Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stress. Life Sci. 1981; 29: 1393-401.
35. Satoh N, Nishimura M, Watanabe Y. Electrophysiologic alterations in the rabbit nodal cells induced by membrane lipid peroxidation. Eur. J. Pharmacol. 1995; 292: 233-40.
36. Wang Y-Z, Jia X-A, Zhao J-Y, Xu G-L. Effects of selenium deficiency on Ca transport function of sarcoplasmic reticulum and lipid peroxidation in rat myocardium. Biol. Trace Element Res. 1993; 36: 159-66.
37. 2+-ATPase by peroxynitrite. Free Radical Res. 1996; 24: 243-59.
38. Hara H, Kato H, Araki T, Onodera H, Kogure K. Involvement of lipid peroxidation and inhibitory mechanisms on ischemic neuronal damage in gerbil hippocampus: Quantitative autoradiographic studies on second messenger and neurotransmitter systems. Neuroscience 1991; 42: 159-69.
39. 2 species on the β-receptor-adenylyl cyclase system. Mol. Cell. Biochem. 1992; 110: 41-6.
40. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and non-sulfhydryl-containing ACE inhibitors. J. Cardiovasc. Pharmacol. 1992; 19: 330-40.
41. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am. J. Physiol. 1992; 263: C851-63.
42. Tan LB, Jorge EJ, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ. Res. 1991; 69: 1185-95.
43. Tompson JA, Hess ML. The oxygen free radical system: A fundamental mechanism in the production of myocardial necrosis. Prog. Cardiovasc. Dis. 1986; 28: 449-62.